Ribavirin therapeutic drug monitoring: why, when and how?
Recent studies suggest the potential interest of ribavirin therapeutic drug monitoring to improve sustain virological response rate in hepatitis C virus-infected patients. The present review details the pharmacokinetic properties of ribavirin, suggesting that it may be a good candidate for therapeutic drug monitoring, the different possible strategies and the analytical methods that could be employed.
Stanke-Labesque
Françoise
F
Service de Pharmacologie-toxicologie, INSERM ERI17, Univ Grenoble, CHU Grenoble, France. fstanke@chu-grenoble.fr
Loustaud-Ratti
Véronique
V
Babany
Gérard
G
Gagnieu
Marie-Claude
MC
Marquet
Pierre
P
D000998:Antiviral Agents / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use; D001682:Biological Availability; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring / Q000379:methods*; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000378:metabolism / Q000821:virology; D006801:Humans; D012254:Ribavirin / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use; D019562:Viral Load
D000998:Antiviral Agents; D012254:Ribavirin